22.418 articles found

Transient dystonia following magnetic resonance imaging in a patient with deep brain stimulation electrodes for the treatment of Parkinson disease. Case report.

Spiegel J, Fuss G, Backens M, Reith W, Magnus T, Becker G, Moringlane JR, Dillmann U.

J Neurosurg · 2003-10-01

DOI: 10.3171/jns.2003.99.4.0772PMID: 14567615

Excessive daytime somnolence in Parkinson's disease. Follow-up after 1 year of treatment.

Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Vanacore N, Meco G.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0118-yPMID: 14598075

Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.

Marini P, Ramat S, Ginestroni A, Paganini M.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0121-3PMID: 14598078

Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?

Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0125-zPMID: 14598082

A paradoxical acute effect of levodopa in de novo parkinsonian patients: worsening of some bradykinetic components.

Pasetti C, Lualdi MM, Pinelli P.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0130-2PMID: 14598087

Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.

Priano L, Albani G, Brioschi A, Guastamacchia G, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0133-zPMID: 14598090

Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.

Stocchi F, Vacca L, Grassini P, Battaglia G, Onofrj M, Valente M, Ruggieri S.

Neurol Sci · 2003-10-01

DOI: 10.1007/s10072-003-0138-7PMID: 14598095

[The surgical capacity for treatment of Parkinson disease with STN stimulation in Denmark].

Østergaard K, Dupont E, Sunde N, Werdelin L.

Ugeskr Laeger · 2003-10-01

PMID: 14610843

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falcão A, Loureiro A, Torrão L, Machado R, Wright L, Soares-da-Silva P.

Eur J Clin Pharmacol · 2003-09-27

DOI: 10.1007/s00228-003-0680-5PMID: 14517707

PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS

CHEN Zhengming, TAFESSE Laykea.

· 2003-09-24

Exo-S-mecamylamine formulation and use in treatment

SHYTLE DOUGLAS, SANBERG PAUL, NEWMAN MARY, SILVER ARCHIE A.

· 2003-09-23

Exo-S-mecamylamine formulation and use in treatment

SHYTLE DOUGLAS, SANBERG PAUL, NEWMAN MARY, SILVER ARCHIE A.

· 2003-09-23